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People  who  inject  drugs  (PWID)  represent  the  core  of the  hepatitis  C virus  (HCV)  epidemic  in  many
countries.  HCV  transmission  continues  among  PWID,  despite  evidence  demonstrating  that  high  coverage
of combined  harm  reduction  strategies,  such  as  needle  syringe  programs  (NSP)  and  opioid substitution
treatment  (OST),  can  be  effective  in reducing  the risk of  HCV  transmission.  Among  infected  individuals,
HCV-related  morbidity  and  mortality  continues  to grow  and  is  accompanied  by major  public  health,
social  and  economic  burdens.  Despite  the  high  prevalence  of HCV  infection,  the  proportion  of  PWID  who
have  been  tested,  assessed  and  treated  for  HCV  infection  remains  unacceptably  low,  related  to systems-,
provider-  and patient-related  barriers  to  care.  This  is despite  compelling  data  demonstrating  that  with
the  appropriate  programs,  HCV  treatment  is  safe  and  successful  among  PWID.  The  approaching  era  of
interferon-free  directly  acting  antiviral  therapy  has  the  potential  to provide  one  of  the  great  advances
in  clinical  medicine.  Simple,  tolerable  and  highly  effective  therapy  will  likely  address  many  of  these
barriers,  thereby  enhancing  the  numbers  of PWID  cured  of  HCV  infection.  However,  the  high  cost  of  new
HCV  therapies  will  be  a barrier  to  implementation  in  many  settings.  This  paper  highlights  that  restrictive
national  drug  policy  and  law  enforcement  are  key  drivers  of  the  HCV  epidemic  among  PWID.  This  paper
also calls  for  enhanced  HCV  treatment  settings  built  on  a  foundation  of both  prevention  (e.g. NSP  and
OST)  and  improved  access  to  health  care  for PWID.
©  2015  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-NDntroduction
The hepatitis C virus (HCV) epidemic has been coined a “viral
ime bomb” by the World Health Organization. HCV is a preva-
ent chronic infection with potentially deadly consequences. Recent
stimates suggest that globally, the HCV viremic (RNA posi-
ive) prevalence is forecasted at 1.1% (0.9–1.4%) corresponding to
0 (64–103) million viremic infections (Gower, Estes, Hindman,
azavi-Shaerer, & Razavi, 2014). Despite the looming public health
hreat that HCV imposes, it receives little public attention. This
ilent disease often progresses with few symptoms, even during
dvanced stages of disease. As a blood borne virus, the major route
f transmission in most countries is injecting drug use. People
ho inject drugs (PWID) are heavily affected by this infectious
isease. However, despite the high prevalence, ongoing transmis-
ion and increasing HCV-related disease burden among PWID, HCV
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testing, prevention, assessment and treatment remain subopti-
mal  in this group, and the time-bomb still ticks on. Over recent
years, the development of simple, tolerable and highly effective
interferon-free directly acting antiviral (DAA)-based therapies for
HCV infection has brought great optimism to the sector. However,
in order for the roll-out of these new IFN-free regimens to elimi-
nate HCV among PWID, drastic changes and the breaking of some
taboos will be required.
Transmission of HCV infection
Although risk factors commonly associated with transmission of
HCV infection include blood transfusion from unscreened donors,
unsafe therapeutic injections, and other health-care related proce-
dures, the majority of new and existing infections in most countries
have occurred as a result of injection drug use (Hajarizadeh,
Grebely, & Dore, 2013). Among PWID, the major route of trans-
mission is through the sharing of drug preparation and injection
equipment (e.g. syringes, needles, ﬁlters, water and cookers)
(Pouget, Hagan, & Des Jarlais, 2012). The hepatitis C virus is
resilient and is capable of surviving on drug preparation equipment
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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e.g. needles, syringes, ﬁlters and water) for several days to
eeks (Doerrbecker et al., 2013; Paintsil, He, Peters, Lindenbach,
 Heimer, 2010). Also, the risk of HCV transmission is greater than
or HIV infection, consistent with greater per contaminated inject-
ng exposure transmission (2.5–5.0% for HCV vs. 0.5%-2.0% for HIV),
nd higher prevalence of HCV than HIV among PWID (and thus, risk
f exposure) (Grebely & Dore, 2011a).
pidemiology of HCV among PWID
Given an estimated global HCV prevalence of 67% among PWID
Nelson et al., 2011), around 10 million PWID have been infected
ith HCV, with an additional large reservoir of infection among
ormer PWID. In some countries, the HCV prevalence is as high
s 90% (Hagan, Pouget, Des Jarlais, & Lelutiu-Weinberger, 2008).
n absolute numbers, the countries with the greatest number of
CV infected PWID include China (1.6 million), the United States
1.4 million) and the Russian Federation (1.3 million) (Nelson et al.,
011).
The estimated incidence of HCV infection among PWID ranges
rom 5% to 45% per annum (Grebely & Dore, 2011a; Hagan et al.,
008; Page, Morris, Hahn, Maher, & Prins, 2013). The risk of HCV
nfection is highest among younger individuals and recent initi-
tes into injecting drug use (Grebely & Dore, 2011a; Page et al.,
013) (2, 3) (1, 2). However, many PWID remain unaware of
heir infection status. The absence of accurate national surveil-
ance and notiﬁcation systems also contributes to underreporting of
CV.
orbidity and mortality among PWID
HCV is a major cause of liver failure and liver-related death
Grebely & Dore, 2014; Hajarizadeh et al., 2013). In the United
tates, HCV-related mortality has now surpassed death related
o HIV (Ly et al., 2012). Globally, the burden of HCV infection is
xpected to substantially increase within the next few decades
Grebely & Dore, 2014; Hajarizadeh et al., 2013).
Given around 25% of people infected with HCV spontaneously
lear virus (4), ∼50% of PWID will have chronic HCV infection (rep-
esents 8 million PWID globally). In those with spontaneous HCV
learance, re-infection in the setting of ongoing HCV exposure is
ossible (Grebely et al., 2012). Although many of those with re-
nfection clear repeatedly, others develop persistent infection.
Development of chronic HCV infection may  lead to progres-
ive hepatic ﬁbrosis, cirrhosis, and complications of liver failure
r hepatocellular carcinoma (Grebely & Dore, 2011b). Progression
o advanced liver disease is uncommon in the initial 10–20 years of
nfection, particularly among PWID who generally acquire infection
t a younger age, but becomes more common with each subse-
uent decade of infection (Grebely & Dore, 2011b). Among PWID,
actors contributing to ﬁbrosis progression such as age, contin-
ed moderate-heavy alcohol use, and HIV are often compounded.
lthough younger individuals with HCV infection are at lower risk
f HCV-related morbidity and mortality, and drug-related mortal-
ty is signiﬁcant among PWID, the ageing cohort nature of PWID
opulations means that liver disease-related mortality is increas-
ng (Grebely & Dore, 2011b, 2014). There is also increasing evidence
hat HCV infection is associated with an increase in both hepatic
nd extra-hepatic disease, including circulatory diseases, renal dis-
ases, and neuropsychiatric disorders (Grebely & Dore, 2011b,
014). However, HCV treatment can attenuate hepatitis C-related
isease consequences, and prevent death associated with HCV (van
er Meer et al., 2012).nal of Drug Policy 26 (2015) S22–S26 S23
Prevention of HCV infection among PWID
There is currently no HCV vaccine. But, HCV infection is a
preventable disease, especially among PWID. Basic requirements
for successful HCV prevention according to the WHO  guidance
are access to health care and justice, health literacy and need
adapted services for PWID (World Health Organisation, 2012). Key
measurements for effective HCV prevention are needle syringe
programs (NSPs, including provision of sterile injection equip-
ment) and opioid substitution treatment (OST) (Turner et al.,
2011). With the combination of these two preventive steps at
high coverage, those in need and at right scale the individual risk
can be minimized (Hagan, Pouget, & Des Jarlais, 2011; Martin,
Hickman, Hutchinson, Goldberg, & Vickerman, 2013; Turner et al.,
2011). In many countries, the coverage of OST  and sterile injec-
tion equipment provision is insufﬁcient (Mathers et al., 2010).
As Page and colleagues have highlighted, even in a country like
the United States, “public health and political efforts to increase
clean syringe/needle availability have been met  with ideological,
social, and political barriers, effectively thwarting the delivery of
one of the most efﬁcacious biomedical technologies for preventing
injection-related infections” (Page et al., 2013).
Most prevention programs, if available at all, are driven by
insights from the ﬁeld of HIV prevention, where a lower cover-
age of needle and syringes is sufﬁcient to stem HIV transmission
compared to HCV (Grebely & Dore, 2011a). However, the higher
infectivity of HCV compared to HIV and greater prevalence
demands broader injecting equipment provision (cooker, ﬁlter,
water), higher coverage and greater scale-up. The requirements for
injecting equipment may  vary by the type of drug used and the type
of users (e.g. a heroin user needs up to 6 sets of injection equip-
ment per day, while a “krokodil (desmorphine)” user may  require
12 sets).
In an attempt to address the HCV epidemic and reduce preva-
lence of infection in the community, prevention measures such
as NSP and OST may  be coupled with HCV treatment (Martin,
Vickerman, et al., 2013). It has been suggested that with even mod-
est rates of HCV treatment uptake it will be possible to substantially
reduce the viral reservoir in the community and decrease the num-
ber of potential sources for transmission, particularly in the era
of IFN-free HCV therapy (Martin, Vickerman, et al., 2013). How-
ever, HCV treatment as prevention will require a strong foundation
of harm reduction programs, such as NSP and OST programs to
reduce ongoing transmission. As such, countries with low cov-
erage of OST and sterile injection equipment provision should
ﬁrst concentrate on the scale-up these two  important prevention
strategies, given their importance in preventing HCV transmis-
sion (Hagan et al., 2011; Martin, Vickerman, et al., 2013; Turner
et al., 2011; Vickerman, Martin, Turner, & Hickman, 2012). Success-
ful HCV prevention strategies among PWID can also prevent HIV
infection, given the similar routes of transmission, higher coverage
and increased scale that are required. However, further research
is needed to better understand the optimal combination of HCV
prevention strategies for reducing HCV transmission.
Any combination of prevention strategies must take into
account that the highest risk of HCV infection is at the beginning of
an injecting career. As such, comprehensive prevention measures
should ensure targeting to new initiates to injecting and young
people who inject drugs (Page et al., 2013).
Access and provision of HCV prevention services is hindered in
countries with restrictive drug law enforcement. The criminaliza-
tion of drug use and the fear of arrest drives people away from
HCV prevention services, resulting in increased risk behaviors and
increased transmission of HCV infection. Restrictions in OST pro-
vision leads to low coverage, thereby limiting the potential effect
on HCV prevention. In countries with repressive drug policy, PWID
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ften end up in prison, where the risk of HCV infection is often
igher, given a high prevalence of HCV infection and the absence
f effective prevention measures.
reatment of HCV infection among PWID
Hepatitis C virus infection is a curable chronic disease. Although
ew DAA-based HCV therapies are already available in some
ountries, for most areas, the current standard of care consists of
reatment with pegylated-interferon (one injection per week), riba-
irin (1–3 tablets twice a day) and telaprevir or boceprevir (6–12
ablets, 2–3 times a day) for those with HCV genotype 1. These
reatments are arduous (6–12 months), poorly tolerated and cure
nly 60–70% of individuals.
Initially, HCV treatment guidelines excluded PWID from consid-
ration, citing concerns about adherence, increased susceptibility
o side effects (e.g. depression) and re-infection (NIH, 1997). How-
ver, there is now compelling evidence that HCV treatment is safe
nd effective among PWID (Aspinall et al., 2013; Dimova et al.,
012). In two systematic reviews of studies assessing treatment
or PWID (one speciﬁcally focusing on those with recent inject-
ng at the time of treatment initiation), the overall proportion with
iral cure was 56% (Aspinall et al., 2013; Dimova et al., 2012). These
esponse rates are comparable to large randomized controlled trials
f HCV treatment (Manns, Wedemeyer, & Cornberg, 2006). Inter-
ational guidelines now recommend treatment for PWID following
ndividualised assessment (Robaeys et al., 2013).
Although there is concern that HCV re-infection may  negate the
otential beneﬁts of treatment, the reported rates of reinfection
ollowing successful HCV treatment among PWID are low (1–5%
er year) (Aspinall et al., 2013). Treatment of HCV infection among
urrent and former PWID has also been demonstrated to be cost-
ffective (Martin et al., 2012).
ew therapies for the treatment of HCV infection
Numerous antiviral agents targeting speciﬁc HCV viral functions
ave been developed (direct acting antivirals [DAAs]) (5). Over the
ext 2–3 years several, interferon free combination DAA regimens
hould be licensed. These regimens offer increased efﬁcacy (>90%),
educed toxicity, shortened treatment durations (8–12 weeks),
impliﬁed dosing (all oral, possibly once-daily regimens) and moni-
oring schedules. The availability of such regimens should markedly
mprove the feasibility of enhanced HCV treatment uptake and
esponses among PWID, further enhancing the prevention poten-
ial of HCV therapy, making elimination of HCV infection among
WID a possibility (Grebely & Dore, 2014; Martin, Vickerman, et al.,
013).
odels of care for the treatment of HCV infection among
WID
Traditionally, the provision of HCV care and treatment has been
rovided at hospital-based specialist services (Bruggmann, 2012).
his setting is often not suitable for PWID, given the risk of stigma-
ization, exclusion due to prejudices and the absence of expertise in
ddiction treatment (Bruggmann & Litwin, 2013). Furthermore, the
imited infrastructure for delivery of HCV therapies and the lack of
CV knowledge in drug and alcohol clinics and primary care centres
ay  limit the ability to provide treatment settings that are suitably
dapted for the needs of this vulnerable population (Bruggmann,
012). A multidisciplinary approach is the foundation of a need-
dapted HCV care setting for PWID (Bruggmann & Litwin, 2013).
lose collaboration of all involved health professionals is crucial for
very model to be successful. To adopt a nonjudgmental attitudenal of Drug Policy 26 (2015) S22–S26
toward PWID is essential for all parties involved. A high level of
acceptance of the individual life circumstances of PWID rather than
rigid exclusion criteria will determine the level of success of any
model of hepatitis C management. Integrating HCV treatment in
a primary care-based, multidisciplinary OST clinic has proven to
be an efﬁcient way  to treat a poly-morbid population of PWID
(Bruggmann & Litwin, 2013).
Barriers to the treatment of HCV infection among PWID
Despite the high prevalence of HCV infection, proven favourable
HCV treatment responses, available guidelines recommending
treatment among PWID, and high treatment willingness, treat-
ment uptake remain as low as 1–2% per year, even in countries
where treatment is available and affordable for everyone (Grebely
& Dore, 2014). Further research is needed to better understand
the best interventions to enhance HCV screening, assessment
and treatment to reduce the burden of HCV infection among
PWID.
Any attempt to avert the public health care threat posed by the
looming burden of HCV among PWID will urgently require ground-
breaking changes to alter the currently inefﬁcient system for the
care of HCV infection among this vulnerable population. A rel-
evant scale-up of treatment among PWID is impossible without
massively reducing the barriers to care. Low awareness (among
patients, health care providers, policy makers, political leadership
and general public), as well as low HCV literacy (among healthcare
professionals and patients) and discrimination and stigmatization
of drug use are all major barriers for PWID to access HCV care
(Bruggmann, 2012; Paterson, Hirsch, & Andres, 2013). Many of
those barriers are a result of the criminalization of drug use (The
Global Commission on Drug Policy, 2013). Repressive drug pol-
icy is hindering effective public health measures for PWID and
therefore fuelling the HCV and HIV epidemic in this population.
De-penalization of drug use would therefore be an important step
toward eliminating hepatitis C (Bruggmann, 2013).
Another major barrier to treatment for PWID is the price of
medication. HCV treatment for both active and former PWID is cost-
effective (driven by the prevention beneﬁt among active PWID)
(Martin et al., 2012; Martin, Vickerman, Miners, & Hickman, 2013).
However, the cost of today’s standard-of care HCV treatment is pro-
hibitively expensive for middle-and low-income countries. Even
in Western European countries, access to current therapies is
restricted because of the exorbitant cost of the medication. High
tolerability of those regimens will bring the potential of high appli-
cability. But, their extortionate cost will exceed even the healthcare
budgets of rich countries. Offering HCV treatment at affordable
prices is crucial in the ﬁght of the global HCV crisis (Bruggmann,
2013).
It is uncertain whether HCV treatment for PWID will be cost-
effective, particularly in the initial era of DAA-based therapy.
Newer, more effective regimens will undoubtedly come at an
increased cost. Price reform and enhanced access to therapy for
those with HCV infection will require considerable public health
advocacy from all sectors in the HCV community, including com-
munity organizations representing PWID. The involvement of
several pharmaceutical companies in development of DAA-based
therapy may  enable more competitive drug pricing in high-income
countries. In low- and middle-income countries, production of
generic DAA regimens will be required, similar to antiretroviral
therapy for HIV.Ultimately, markedly enhanced global public health advocacy
and investment along the lines of the Global Fund for HIV, tuber-
culosis and malaria, will be required to enable broadened access to
highly effective HCV therapy, including for PWID.
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HCV infection is widely ignored politically, resulting in low
ttention, resources and commitment. Political efforts to improve
revention and access to care and to secure affordable treatment lag
ar behind those of HIV. With the availability of novel, highly efﬁ-
acious HCV therapies, the elimination of HCV among PWID is now
easible. At this moment, evidence-based harm reduction measures
nd speciﬁc care elements need to be optimized and expanded in
rder to efﬁciently prevent the further spread and secondary liver
isease burden of HCV and to halt the growing individual, social
nd economic harm of the epidemic.
onclusion
HCV infection is highly prevalent among PWID. Globally, 67% of
WID are HCV positive.
Awareness is low among policy makers, political leadership
nd general public, particularly in the regions most affected by
he HCV epidemic among PWID. Despite this, the public health
hreat is considerable and will manifest itself in the next ﬁve
ears.
Overall, only 10–50% of all PWID worldwide receive HCV test-
ng, less than 10% have access to assessment and treatment of the
isease, despite the evidence that treatment is effective. Restric-
ive drug policy and law enforcement are key drivers of the HCV
pidemic among PWID, in even greater magnitude than of HIV,
s HCV is more contagious and 3.5 times more prevalent. Suc-
essful HCV prevention strategies combine high coverage of harm
eduction measures with HCV treatment provision at the right
cale. The integration of needs-adapted HCV treatment services
nto harm reductions services like opioid substitution treatment
as the potential to enhance therapy uptake and cure rates. Novel,
ell-tolerated, and efﬁcacious interferon-free HCV treatment regi-
ens administered once daily as a pill over 8–12 weeks bring along
he potential to cure the majority of infected people who  inject
rugs. With these new medicines, the elimination of HCV among
WID becomes achievable. The contents and conclusions of the
aper reﬂect a broad consensus among social and clinical scien-
ists participating in a UNODC Scientiﬁc Consultation on HIV/AIDS
UNODC, 2014).
Conclusion Statements:
- HCV prevalence is high among PWID. Globally, 67% of PWID
are HCV positive.
- The public health threat by the HCV epidemic is considerable
and will continuously increase in the next years. Still, Hep-
atitis C awareness is generally low, even among health care
providers and health ministries, particularly in the regions
most affected by the HCV epidemic among PWID.
- Access to testing, assessment and treatment for PWID is poor,
despite the evidence that treatment is effective.
- The HCV epidemic among PWID is relevantly driven by
restrictive drug policy and law enforcement.
- HCV can be prevented by a combination of high coverage of
harm reduction measures with HCV treatment provision at
the right scale.
- Treatment uptake and cure rates can be enhanced by the pro-
vision of HCV care integrated into harm reductions services
like opioid substitution treatment.
- New interferon-free HCV treatment regimens have the poten-
tial to cure the majority of infected people who inject drugs.
With these well tolerated and easy to administer medicines,
the elimination of HCV among PWID becomes achievable.nal of Drug Policy 26 (2015) S22–S26 S25
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